NDA 206307 · Fonseca Biosciences
Xtoro
Finafloxacin · Otic · Quinolone Antimicrobial
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Mar 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Dec 17, 2014
Approved uses
1
Original approval plus efficacy supplements
Registered trials
7
0 Phase 3, 0 recruiting
FAERS reports
1
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 24, 2026.
XTORO® is indicated for the treatment of acute otitis externa (AOE) with or without an otowick, caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus in patients age 1 year and older. XTORO® is a quinolone antimicrobial indicated for the treatment of acute otitis externa (AOE) caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus . ( 1 )
Mechanism: Finafloxacin is a fluoroquinolone antimicrobial [see Microbiology ( 12.4 )] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 17, 2014 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewSummary ReviewPediatric Medical Review
1 products under this application
- XTORO · FINAFLOXACIN 0.3% · SUSPENSION/DROPS, OTIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Finafloxacin" as an intervention, any sponsor and status, largest first.
- Finafloxacin for the Treatment of cUTI and/or Acute PyelonephritisPivotal-lookingCompleted
MerLion Pharmaceuticals GmbHIndustry
NCT01928433 · 225 participants · Start Dec 2012 · Primary completion Jun 2014
Drug: Finafloxacin 800 mg i.v. once daily; Finafloxacin placebo i.v. once daily and 6 more · For: Urinary Tract Infections; Acute Pyelonephritis
Sites: Giessen, Germany
MerLion Pharmaceuticals GmbHIndustry
NCT00483158 · 95 participants · Start Aug 2007 · Primary completion May 2008
Drug: Finafloxacin hydrochloride · For: Helicobacter Infections; Urinary Tract Infection
Sites: Basel, Switzerland
- Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy SubjectsCompleted
MerLion Pharmaceuticals GmbHIndustry
NCT01910883 · 58 participants · Start Sep 2010 · Primary completion Mar 2012
Drug: Finafloxacin i.v. solution 200 mg; Finafloxacin i.v. solution 400 mg and 4 more · For: Healthy
Sites: Leeds, United Kingdom
MerLion Pharmaceuticals GmbHIndustry
NCT01904162 · 40 participants · Start Feb 2010 · Primary completion Feb 2010
Drug: 400 mg finafloxacin (2 x 200 mg tablets) · For: Pharmacokinetic and Tolerability of Finafloxacin
Sites: Tempe, Arizona
MerLion Pharmaceuticals GmbHIndustry
NCT00722735 · 36 participants (planned) · Start Oct 2008 · Primary completion Apr 2009
Drug: Finafloxacin; Ciprofloxacin · For: Urinary Tract Infections
Sites: Marburg, Germany; Singapore, Singapore
MerLion Pharmaceuticals GmbHIndustry
NCT00723502 · 30 participants (planned) · Start Sep 2008 · Primary completion Apr 2009
Drug: Finafloxacin + Amoxicillin; Finafloxacin + Esomeprazole · For: Gram-Negative Bacterial Infections; Helicobacter Infections; Dyspepsia
Sites: Marburg, Germany
MerLion Pharmaceuticals GmbHIndustry
NCT01907867 · 18 participants · Start Jan 2012 · Primary completion Feb 2012
Drug: Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days · For: Safety and Tolerability
Sites: Phoenix, Arizona
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dysarthria1
- dysphagia1
- dysphonia1
- dyspnoea1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacokinetics of Intravenous Finafloxacin in Healthy Volunteers.
Taubert M, Chiesa J, Lückermann M, et al. · Antimicrob Agents Chemother 2017 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers.
Patel H, Andresen A, Vente A, et al. · Antimicrob Agents Chemother 2011 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections.
Wagenlehner F, Nowicki M, Bentley C, et al. · Antimicrob Agents Chemother 2018 · Clinical Trial, Phase II, Randomized Controlled Trial
- Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: A systematic review and meta-analysis of randomized controlled trials.
Hung KC, Tsai WW, Hsu CW, et al. · Int J Antimicrob Agents 2023 · Meta-Analysis, Systematic Review
- Efficacy and Safety of Finafloxacin Otic Suspension, 0.3% for the Treatment of Acute Otitis Externa: Results from two Phase III Randomized Clinical Studies.
Edmunds A, Bentley C, Lückermann M, et al. · Ann Otol Rhinol Laryngol 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Early Clinical Assessment of the Antimicrobial Activity of Finafloxacin Compared to Ciprofloxacin in Subsets of Microbiologically Characterized Isolates.
Vente A, Bentley C, Lückermann M, et al. · Antimicrob Agents Chemother 2018 · Clinical Trial, Phase II, Randomized Controlled Trial
Sponsor: Fonseca Biosciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.